Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib

Fig. 7

Sorafenib was identified as a ferroptosis inducer expected to treat high-risk Ph-neg B-ALL patients. A The protein-protein interaction network composed of the genes correlated Sorafenib. (Red: significantly up-regulated genes in ‘High-risk’ group or ‘Middle-risk’ group; green: significantly down-regulated genes in ‘High-risk’ group or ‘Middle-risk’ group; blue: the genes with no significance among three groups) B-G The expression of six genes correlated with the susceptibility of Sorafenib among three clusters. H The Sorafenib sensitivity scores of the samples in three groups calculated with the expression of six Sorafenib sensitivity related genes. I Sorafenib sensitivity related gene expression of three representative B-ALL cell lines recorded in CCLE database were shown in the form of log10(RPKM). J Combined the gene expression of the three cell lines, each cell line was ranked with a sorafenib sensitivity score (blue). Analyzed with the sensitivity of three cell lines to Sorafenib (red, evaluated with IC50), we validated the higher the sorafenib sensitivity score was, the more sensitive to Sorafenib B-ALL was

Back to article page